Currently, out of the existing stock ratings of Paul Matteis - 179 which are a Buy (72.76%), 67 which are a Hold (27.24%)

Paul Matteis

Work Performance Price Targets & Ratings Chart

Analyst Paul Matteis works at STIFEL and is covering the Healthcare sector with 482 price targets and ratings displayed on 34 stocks. Previously, Paul Matteis worked at LEERINK.

Paul Matteis's average stock forecast success ratio is 53.13% with an average time for price targets to be met of 148.52 days.

Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 22-Nov-2023.

Wall Street Analyst Paul Matteis

Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.

Average potential price target upside

of $37.76 (18.11%) on VRTX (VERTEX PHARMACEUTICALS).
of $36.08 (30.11%) on GWPH.
of $33.2 (12.52%) on BIIB (BIOGEN).

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ALKS Alkermes plc ALNY Alnylam Pharmaceuticals ALXN ATHA Athira Pharma BIIB Biogen BMRN BioMarin Pharmaceutical CERE Cerevel Therapeutics Holdings GWPH IONS Ionis Pharmaceuticals KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRVL SAGE Sage Therapeutics VRTX Vertex Pharmaceuticals ZGNX Zogenix AVDL Avadel Pharmaceuticals plc DYN KALV GMTX QURE uniQure N.V ALEC PRTK Paratek Pharmaceuticals ABOS ELYM WVE Wave Life Sciences Ltd XENE Xenon Pharmaceuticals AKCA AKAO CDTX Cidara Therapeutics DNLI Denali Therapeutics NBRV OREX

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Uy Ear (MIZUHO)